Healthy Inc > Blog > Levodopa Carbidopa manufacturer India
Posted on:

Can levodopa cause diarrhea?

In the pharmaceutical industry, Levodopa (standardly combined with Carbidopa or Benserazide) is the gold standard for Parkinson’s disease. As a pharmacist and manufacturer, I can confirm that diarrhea is a recognized side effect, though it is statistically less common than nausea or constipation.

At your WHO-GMP facility in Mumbai, where you likely manufacture Levodopa/Carbidopa FDCs, it is vital to distinguish between a mild reaction and a serious complication like Drug-Induced Enteropathy.

Clinical Causes of Diarrhea with Levodopa

Gastrointestinal Motility Changes: Levodopa acts on dopamine receptors in the gut. While it often slows motility (causing constipation), in some patients, it can trigger hypermotility, leading to diarrhea.

The “Entacapone” Factor: If your firm produces the Triple Combination (Levodopa + Carbidopa + Entacapone), the risk of diarrhea increases significantly. Entacapone (a COMT inhibitor) is notorious for causing delayed-onset, severe, and persistent diarrhea, often occurring weeks or months after starting therapy.

Excipient Sensitivity: Occasionally, the diarrhea is not caused by the API but by the fillers used in the tablet, such as lactose or sugar alcohols (sorbitol/mannitol), especially if the patient has a pre-existing intolerance.

Mechanism: Peripheral Dopamine Activation

  • Peripheral Conversion: If Levodopa is converted to dopamine before it crosses the blood-brain barrier, it can stimulate D2 receptors in the mesenteric plexus.

  • The Result: This can lead to local irritation and changes in fluid secretion in the bowels. This is why we always combine Levodopa with a peripheral decarboxylase inhibitor like Carbidopa—to keep the dopamine in the brain and out of the gut.

The Pharmacist’s “Technical Warning”

  • Severe Dehydration: In Parkinson’s patients (who are often elderly), persistent diarrhea can lead to rapid dehydration and electrolyte imbalance, which can worsen motor “off” symptoms and cause confusion.

  • The “Entacapone Switch”: If a patient on the triple combination develops chronic diarrhea, the doctor may need to switch them back to a Carbidopa/Levodopa-only formulation.

  • Probiotic Support: While not a clinical cure, some patients find relief by adding a high-quality probiotic to balance the gut flora during the adjustment period.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Dispersible” USP: On your digital platform, consider highlighting Dispersible Levodopa/Carbidopa Tablets. These are excellent for patients with “morning akinesia” or swallowing difficulties, as they absorb faster and may bypass some of the gastric irritation associated with standard tablets.

  • Stability for Export: Levodopa is highly sensitive to oxidation and light. For export to Zone IVb tropical regions, using Alu-Alu blister packaging is mandatory to prevent the tablets from turning dark (oxidizing) and losing potency.

  • Dossier Support: We provide full CTD/eCTD Dossiers for various ratios (1:4 and 1:10) to support your firm’s registration in international neurology tenders.

Carbidopa and Levodopa Tablets

Posted on:

What is the brand name for levodopa and carbidopa combination?

In the pharmaceutical industry, the combination of Levodopa and Carbidopa is the “Gold Standard” for the management of Parkinson’s disease. As a pharmacist and manufacturer, I classify this as a dopamine precursor and decarboxylase inhibitor combination.

While Sinemet is the global innovator brand, there are several key regional and generic brands that are highly relevant for your B2B marketplace and export operations.

Primary Brand Names

RegionBrand NameManufacturer (Innovator/Major)
Global / USASinemetMerck (Innovator) / Organon
IndiaSyndopaSun Pharmaceutical Industries
IndiaLCDIntas Pharmaceuticals
IndiaTidometTorrent Pharmaceuticals
Global (Extended Release)RytaryAmneal Pharmaceuticals
Global (Intestinal Gel)DuopaAbbVie

Mechanism: The “Trojan Horse” Strategy

The reason these two are combined is a classic example of pharmacokinetic synergy. Levodopa alone is highly inefficient because it is destroyed before it reaches the brain.

Levodopa (The Precursor): Levodopa can cross the Blood-Brain Barrier (BBB). Once inside the brain, it is converted into Dopamine, restoring the levels needed for smooth muscle movement.

Carbidopa (The Protector): Carbidopa cannot cross the BBB. Its job is to stay in the bloodstream and block the enzyme DOPA Decarboxylase. This prevents Levodopa from being converted to dopamine in the body (periphery).

The Result: By protecting Levodopa in the bloodstream, Carbidopa allows more of it to reach the brain. This also significantly reduces side effects like severe nausea and vomiting caused by dopamine in the blood.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your WHO-GMP facility in Mumbai, this combination is a high-precision CNS (Central Nervous System) product:

  • The 4:1 and 10:1 Ratios: On your marketplace, you should highlight that you offer standard ratios like 100/10 mg, 100/25 mg, and 250/25 mg. Explaining these ratios to B2B buyers shows your technical manufacturing expertise.

  • Extended Release (CR) Formulations: Promoting a Controlled Release (CR) version is a major USP. It reduces “wearing-off” effects for patients, making your product more attractive to international hospital networks.

  • Stability & Moisture Sensitivity: Levodopa is sensitive to light and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 36-month shelf life, which is essential for export to tropical Zone IVb regions.

  • Dossier Readiness: Since Parkinson’s requires lifelong treatment, we maintain full CTD/eCTD Dossiers to support your firm in bidding for long-term government health contracts and insurance tenders.

Carbidopa and Levodopa Tablets

Posted on:

What is Carbidopa Levodopa 25-250 mg used for?

In the pharmaceutical industry, Carbidopa and Levodopa (25 mg/250 mg) is the “gold standard” therapy for managing Parkinson’s Disease. As a pharmacist, I view this specific ratio as a highly sophisticated delivery system designed to ensure that the maximum amount of active medication reaches the brain while minimizing systemic side effects.

Primary Clinical Uses

  • Idiopathic Parkinson’s Disease: To alleviate the primary symptoms: resting tremors, muscular rigidity, and bradykinesia (slowness of movement).

  • Post-Encephalitic Parkinsonism: Used for movement disorders following certain viral brain infections.

  • Symptomatic Parkinsonism: Treating movement issues resulting from carbon monoxide or manganese poisoning.

    Mechanism of Action: The Synergy

This combination works by restoring dopamine levels in the brain, but it requires two components to work effectively:

Levodopa (The Precursor): Dopamine cannot cross the Blood-Brain Barrier (BBB). Levodopa is a precursor that can cross the BBB. Once inside the brain, it is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase.

Carbidopa (The Protector): If Levodopa is taken alone, 95% of it is converted to dopamine in the bloodstream before it reaches the brain. This causes severe nausea and prevents the drug from working. Carbidopa is a decarboxylase inhibitor that does not cross the BBB. It “protects” the Levodopa in the bloodstream, allowing it to reach the brain intact.

Technical Formulation & Dosage (25/250)

  • The 1:10 Ratio: The 25 mg/250 mg strength is a common maintenance dose. Clinical research shows that at least 70 mg to 100 mg of Carbidopa per day is typically required to fully saturate the peripheral decarboxylase enzymes.

  • On-Off Phenomenon: As a pharmacist, I monitor patients for the “wearing-off” effect, where symptoms return before the next dose is due. This often requires precise titration.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, this CNS (Central Nervous System) drug requires rigorous quality control:

  • Content Uniformity: Because Parkinson’s patients are highly sensitive to dose fluctuations, our WHO-GMP manufacturing process uses validated double-blending to ensure that the 25 mg of Carbidopa is perfectly distributed within the 250 mg of Levodopa.

  • Stability & Sensitivity: Levodopa is sensitive to light and oxidation. We utilize Alu-Alu blister packaging or opaque HDPE bottles to ensure a 24-month shelf life, especially for export to Zone IVb regions (hot and humid) like Africa and Southeast Asia.

  • Global B2B Demand: This is a high-value, recurring maintenance medication. Our Mumbai facility provides full CTD/eCTD Dossiers to support international partners in registering the product for hospital tenders and private distribution.

Carbidopa and Levodopa Tablets

Posted on:

What is Carbidopa Levodopa 10 100 mg used for?

In the pharmaceutical industry, Carbidopa (10 mg) and Levodopa (100 mg) tablets are the definitive “gold standard” for the treatment of Parkinson’s disease. As a pharmacist, I characterize this combination as a metabolic precursor strategy designed to replenish dopamine in the brain while minimizing systemic side effects.

Primary Clinical Uses

  • Idiopathic Parkinson’s Disease: Used to manage the primary motor symptoms, including tremors (shaking), rigidity (muscle stiffness), and bradykinesia (slowness of movement).

  • Post-Encephalitic Parkinsonism: Treatment of symptoms following viral brain infections.

  • Symptomatic Parkinsonism: Relief of motor deficits resulting from carbon monoxide poisoning or manganese intoxication.

Mechanism of Action: The Brain-Barrier Strategy

This combination is a classic example of pharmacokinetic synergy:

Levodopa (The Precursor): Levodopa is the immediate metabolic precursor of dopamine. Unlike dopamine itself, Levodopa can cross the Blood-Brain Barrier (BBB). Once inside the brain, it is converted into dopamine by the enzyme L-amino acid decarboxylase.

Carbidopa (The Protector): If Levodopa were taken alone, most of it would convert to dopamine in the bloodstream before reaching the brain, causing severe nausea and vomiting. Carbidopa is a peripheral decarboxylase inhibitor; it does not cross the BBB. It “protects” the Levodopa in the bloodstream, allowing more of it to reach the brain while significantly reducing peripheral side effects.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Carbidopa/Levodopa is a high-precision CNS (Central Nervous System) medication:

  • 1:10 Ratio Precision: The 10/100 mg strength maintains the critical ratio required for initial titration. As a WHO-GMP manufacturer, we utilize validated blending processes to ensure absolute content uniformity, as even minor deviations can impact the patient’s motor control (the “on-off” effect).

  • API Stability: Both APIs are sensitive to light and moisture. We utilize Alu-Alu blister packaging to prevent degradation and ensure a 24-month shelf life, which is essential for export to tropical Zone IVb regions.

  • Niche Market Demand: While common, this is a specialized product for neurology-focused B2B distributors and hospital supply chains. Our Mumbai hub provides the CTD/eCTD Dossiers and bioequivalence data required for international registration.

  • Formulation Varieties: Beyond immediate-release (IR) tablets, we also evaluate extended-release (CR) formulations to provide more stable plasma levels for advanced-stage patients.

Carbidopa and Levodopa Tablets

Add to cart